VBIONasdaqPharmaceutical PreparationsFiscal year ends December 31

Valion Bio, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$1.16−0.01 (-0.85%)

Close on Oct 19, 2026

Market cap: $3.92M
P/E (TTM): –
Dividend yield: –

Valion Bio, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	–	0.78	1.18	1.84	1.26
Cost of Revenue	–	0.78	0.89	1.54	1.30
Gross Profit	–	0.00	0.29	0.30	-0.04
Research & Development	3.13	1.31	1.66	1.73	0.88
Selling, General & Admin	4.77	3.16	6.88	8.67	4.72
Selling & Marketing	–	1.19	2.13	2.79	1.79
General & Administrative	–	3.16	4.75	5.88	2.93
Advertising Expenses	–	0.50	0.80	1.30	0.66
Operating Expenses	7.90	4.48	8.53	10	5.60
Operating Income	-7.90	-4.48	-8.25	-10	-5.63
Interest Expense	0.15	0	–	–	–
Interest & Investment Income	0.02	0.01	–	–	–
Other Non-Operating Income	-0.10	0.01	0.00	0.00	-2.86
Asset Impairment Charges	–	0	0	0	0
Pretax Income	–	–	-8.24	-10	–
Income Tax Expense	0	0	–	–	–
Income from Continuing Operations	-7.99	-4.47	–	–	–
Income from Discontinued Operations	-0.89	-1.19	–	–	–
Net Income incl. Noncontrolling Interests	–	-5.66	-8.24	-10	-8.49
Net Income	-8.88	-5.66	-8.24	-10	-8.49
EPS (Basic)(per share)	-7.84	-19.68	-176.80	-1,773.44	-4,131.00
EPS (Diluted)(per share)	–	-19.68	-176.80	-1,773.44	-4,131.00
Shares Outstanding (Basic, Weighted)(shares)	1.16	0.29	0.05	0.01	0.00
Shares Outstanding (Diluted, Weighted)(shares)	1.16	0.29	0.05	0.01	0.00
EBITDA	–	-4.47	-8.24	-10	–
Net Interest Income	–	0.01	0.00	0.00	-1.82

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -91.8%

Financial strength

Current ratio: 1.11
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 69.2%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.92
Dividend yield: –